Alnylam Pharmaceuticals, INC. (ALNY) — SEC Filings

Overview

Alnylam Pharmaceuticals, INC. (ALNY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 11, 2025: On December 10, 2025, Alnylam Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and business operations. No specific new material events or finan

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 2 bullish, 36 neutral, 1 mixed. The dominant filing sentiment for Alnylam Pharmaceuticals, INC. is neutral.

Filing Type Overview

Alnylam Pharmaceuticals, INC. (ALNY) has filed 1 ARS, 3 DEFA14A, 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 10 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (39)

• ARS Filing — ARS · Apr 6, 2026
• DEFA14A Filing — DEFA14A · Apr 6, 2026
• Alnylam Pharmaceuticals Files 8-K — 8-K · Dec 11, 2025 Risk: low
  On December 10, 2025, Alnylam Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," i
• 8-K Filing — 8-K · Dec 3, 2025
• Alnylam Swings to Profit on Soaring Product & Collaboration Revenue — 10-Q · Oct 30, 2025 Risk: medium
  Alnylam Pharmaceuticals, Inc. (ALNY) reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $127.3
• Alnylam Pharmaceuticals Enters Material Definitive Agreement — 8-K · Oct 3, 2025 Risk: medium
  On September 30, 2025, Alnylam Pharmaceuticals, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, headquar
• Alnylam Pharmaceuticals Reports Material Agreement and Equity Sales — 8-K · Sep 12, 2025 Risk: medium
  On September 12, 2025, Alnylam Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial
• Alnylam Pharmaceuticals Files 8-K Report — 8-K · Sep 10, 2025 Risk: low
  On September 10, 2025, Alnylam Pharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The report was filed as of September 1
• Alnylam's Q2 Revenue Soars 60% on Strong Product & Collaboration Growth — 10-Q · Jul 31, 2025 Risk: medium
  Alnylam Pharmaceuticals reported a significant increase in total revenue for the three and six months ended June 30, 2025. Total revenue for the second quarter
• Alnylam Pharmaceuticals Appoints New Chief Medical Officer — 8-K · Jun 18, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. announced on June 18, 2025, that its Board of Directors appointed Dr. Blake R. Wilson as Chief Medical Officer, effective June 12,
• Alnylam Pharmaceuticals Files 8-K on Governance Matters — 8-K · May 13, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. filed an 8-K on May 13, 2025, reporting events that occurred on May 8, 2025. The filing primarily concerns amendments to its artic
• Alnylam Pharmaceuticals Q1 2025 Update — 10-Q · May 1, 2025 Risk: medium
  Alnylam Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The filing details financial performance and business operations
• Alnylam Pharmaceuticals Files Proxy Statement Amendment — DEFA14A · Apr 4, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. filed an amendment (Amendment No. 1) to its Definitive Proxy Statement on April 4, 2025. This filing is related to the solicitatio
• Alnylam Pharmaceuticals Files Proxy Materials — DEFA14A · Mar 24, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. filed a Definitive Additional Materials proxy statement on March 24, 2025. This filing is related to the company's proxy statement
• Alnylam Pharma Files 2025 Proxy: Executive Equity Awards Detailed — DEF 14A · Mar 24, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. filed its DEF 14A on March 24, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and e
• Alnylam Pharmaceuticals Files 8-K Report — 8-K · Mar 21, 2025 Risk: low
  On March 20, 2025, Alnylam Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financi
• Alnylam Pharmaceuticals Appoints New Directors, Adjusts Executive Pay — 8-K · Mar 5, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. announced on March 3, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two ne
• Alnylam Pharmaceuticals Files 2024 10-K — 10-K · Feb 13, 2025 Risk: medium
  Alnylam Pharmaceuticals, Inc. filed its 2024 10-K on February 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Cambridge,
• Alnylam Pharmaceuticals Reports Financial Condition — 8-K · Jan 13, 2025 Risk: low
  Alnylam Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on Results of Operations and Financial Condition as of January 12, 2025. The filing do
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• Alnylam Pharmaceuticals Q3 2024 Update — 10-Q · Oct 31, 2024 Risk: medium
  Alnylam Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance, including product and collabora
• SC 13G/A Filing — SC 13G/A · Aug 12, 2024
• Alnylam Pharmaceuticals Q2 2024 10-Q Filing — 10-Q · Aug 1, 2024 Risk: medium
  Alnylam Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance, including product and collaboration
• SC 13G/A Filing — SC 13G/A · Jul 5, 2024
• Alnylam Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · May 20, 2024 Risk: low
  Alnylam Pharmaceuticals, Inc. filed an 8-K on May 20, 2024, reporting on matters submitted to a vote of security holders as of May 16, 2024. The filing details
• Alnylam Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: medium
  ALNYLAM PHARMACEUTICALS, INC. (ALNY) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Alnylam Pharmaceuticals reported financial results for the qua
• Alnylam Pharmaceuticals Files Definitive Proxy Statement — DEF 14A · Apr 1, 2024 Risk: low
  ALNYLAM PHARMACEUTICALS, INC. (ALNY) filed a Proxy Statement (DEF 14A) with the SEC on April 1, 2024. Alnylam Pharmaceuticals, Inc. filed a Definitive Proxy Sta
• Alnylam Pharmaceuticals Appoints New CMO and Director — 8-K · Mar 4, 2024 Risk: low
  Alnylam Pharmaceuticals, Inc. announced on March 4, 2024, the appointment of Dr. Pushkal Chandra as Chief Medical Officer and the election of Dr. Alnylam Pharma
• Alnylam Pharmaceuticals, Inc. Files 2023 Annual Report (10-K) — 10-K · Feb 15, 2024 Risk: medium
  ALNYLAM PHARMACEUTICALS, INC. (ALNY) filed a Annual Report (10-K) with the SEC on February 15, 2024. Alnylam Pharmaceuticals, Inc. filed its 2023 10-K report on
• Alnylam Files 8-K on Financial Results and Operations — 8-K · Feb 15, 2024 Risk: medium
  Alnylam Pharmaceuticals, Inc. filed an 8-K on February 15, 2024, to report on its Results of Operations and Financial Condition, and to include Financial Statem
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Capital World Investors Cuts ALNY Stake to 13.5% — SC 13G/A · Feb 9, 2024 Risk: medium
  Capital World Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, disclosing a decrease in its beneficial ownership of Aln
• FMR LLC & Abigail Johnson Disclose 8.239% Stake in Alnylam Pharma — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their holdings in Alnylam Pharmaceuticals Inc. As of December 31, 20
• Wellington Management Amends Alnylam Pharma Stake (12th Update) — SC 13G/A · Feb 9, 2024 Risk: low
  Wellington Management Group LLP, a major investment firm, filed an amendment (SC 13G/A) on February 9, 2024, updating its ownership in Alnylam Pharmaceuticals,
• Baillie Gifford Updates Alnylam Pharma Stake (SC 13G/A) — SC 13G/A · Jan 29, 2024
  Baillie Gifford & Co, a prominent investment management firm, filed an amended SC 13G/A on January 29, 2024, indicating a change in their ownership of Alnylam P
• BlackRock Amends ALNYLAM PHARMACEUTICALS Stake (SC 13G/A) — SC 13G/A · Jan 26, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating a change in its ownership of ALNYLAM PHARMACEUTICALS, INC. common stock as of December
• Alnylam 8-K: Officer Compensation, Director Changes Reported — 8-K · Jan 19, 2024
  Alnylam Pharmaceuticals, Inc. filed an 8-K on January 19, 2024, reporting events that occurred on January 12, 2024. This filing primarily concerns changes in co
• Alnylam 8-K Signals Upcoming Financial Disclosure — 8-K · Jan 8, 2024
  Alnylam Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024, related to "Results of Operations and Financ

Related Companies

NVS · REGN

Frequently Asked Questions